Form 4: Health Catalyst General Counsel Sells Shares Under 10b5-1 Trading Plan

Health Catalyst's General Counsel, Benjamin Landry, sold 2,500 shares of common stock at $7.5182 per share on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Benjamin Landry, the General Counsel of Health Catalyst, Inc., sold 2,500 shares of common stock on January 6, 2025.
• The sale was executed at a price of $7.5182 per share.
• This transaction was conducted under a pre-established Rule 10b5-1 trading plan adopted on March 1, 2024.
• Following the transaction, Mr. Landry directly owns 72,250 shares of Health Catalyst stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.

Industry Context

This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies to avoid accusations of insider trading.
• The sale of 2,500 shares is a relatively small transaction compared to the total number of shares outstanding for Health Catalyst, and is not unusual for an executive's trading activity.
• Similar transactions are regularly reported by executives at comparable companies in the healthcare technology sector.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on investor sentiment, but is unlikely to significantly affect the company's operations or financial health.

Key Dates

Keywords

Health Catalyst, HCAT, insider trading, Form 4, 10b5-1 plan, stock sale, Benjamin Landry, General Counsel